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1. INTRODUCTION & PURPOSE 
This document details the statistical analyses that will be undertaken and the presentation that 
will be followed, as closely as possible, when analysing and reporting the 15-year median follow-
up results from the CAP study (Cluster randomised trial of testing for prostate cancer). Readers 
are referred to the main statistical analysis plan (Metcalfe et al, 2016) and published papers 
(Turner et al 2014, Martin et al 2018) for further details of the CAP design, conduct, data, and 
primary analysis. 
The purpose of the plan is to:  
1. Ensure that the analysis is appropriate for the aims of the trial, reflects good statistical 
practice, and that interpretation of a priori and post hoc analyses respectively is appropriate. 
2. Explain in detail how the data will be handled and analyzed to enable others to perform the 
analysis in the event of sickness or other absence 
 
Additional exploratory or auxiliary analyses of data not specified in the protocol are permitted but 
fall outside the scope of this analysis plan. Such analyses would be expected to follow Good 
Statistical Practice. 
The analysis strategy will be made available if required by journal editors or referees when the main 
papers are submitted for publication.  Additional analyses suggested by reviewers or editors will, if 
considered appropriate, be performed in accordance with the Analysis Plan, but if reported the 
source of such a post-hoc analysis will be declared. 
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2. SYNOPSIS OF STUDY DESIGN AND PROCEDURES 
The information in this section is extracted from the study protocol (Turner et al, 2014) with the 
single purpose of ensuring an informed statistical analysis. For all other purposes reference 
MUST be made to the current version of the protocol. 
2.1. Trial aims and objectives 
To evaluate the effectiveness and cost-effectiveness of population screening for prostate cancer 
by establishing a cluster randomised trial allocating general practices to either intensive case-
finding (the ProtecT trial) or unscreened standard practice. 
The objectives are: 
1) To provide an unbiased estimate of the effect of a single invitation to screening for prostate 
cancer on prostate cancer-specific and all-cause mortality in the population. 
2) To contribute to the international effort to investigate the impact of prostate cancer screening. 
3) To estimate the cost implications of prostate cancer screening and use the data collected to 
develop and refine a probabilistic model of the cost-effectiveness of prostate cancer screening 
in the UK. 
The primary analysis addressing these objectives has been published (Martin, 2018). These same 
objectives will be addressed in an analysis of clinical events occurring by the median 15-year follow 
up point: 31st March 2021. 
2.2. Trial design and configuration 
 
aCluster randomization was blocked and stratified by geographical area.  
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2.3. Trial centres 
Sheffield, Newcastle, Bristol, Cardiff, Birmingham, Leicester, Cambridge, Leeds. 
2.4. Eligibility criteria 
2.4.1. Inclusion criteria 
Men aged 50 to 69 years, registered at a participating GP practice. All GP practices in the study 
areas were eligible to participate and were included in the random allocation. 
2.4.2. Exclusion criteria 
Men identified as already having a prostate cancer diagnosis on or before the date on which the 
list of men is generated for a practice. Men excluded by the study consent process (see protocol). 
2.5. Description of interventions 
The intervention was a single invitation to PSA testing at a dedicated prostate cancer check clinic 
at or near the man’s GP practice. Those men found to have a high PSA level were invited to 
undergo a diagnostic biopsy. Those men found to have clinically localised prostate cancer were 
invited to have their management randomised in the ProtecT trial of surgery, radiotherapy, and 
conservative management. 
The comparison was standard NHS practice; GPs discussed the risks and potential benefits with 
those men requesting a PSA test. 
2.6. Randomisation procedures 
The CaP study was cluster randomised. At each study centre, neighbouring groups of eight to 
twelve GP practices were block-randomised in a 1:1 ratio to PSA testing as part of the ProtecT 
study, or to NHS usual care in the comparison group. When the group included an odd number of 
practices, the greater number were allocated to the intervention group. This randomisation was 
done by an independent statistician (S Brookes) with no other involvement with the study. The 
randomisation preceded approaches to the GP practices; practices were invited to participate in 
the group of the study they were allocated to. Allocation was based on random numbers 
generated using the contemporary version of Stata statistical software (College Station, TX, USA). 
2.7. Blinding 
Members of the cause of death committee see patient vignettes, prepared to obscure the study 
group the patient is in. Hence decisions about the cause of death are made blind to intervention 
group (Williams et al, 2015).  
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2.8. Outcome measures 
2.8.1. Primary outcome 
The primary outcome was prostate cancer mortality at a median ten years after start of follow up; 
analysis of this outcome has been reported (Martin, 2018). The primary outcome for the 15-year 
analysis is definite or probable prostate cancer mortality after a median 15 years of follow-up, 
which was originally pre-specified in the secondary outcomes (see below). 
Time zero for this outcome is the list date for the man’s GP practice. Failure time, or censoring 
time, is the date on which a man dies, on which the man has left England and Wales, or the 
dataset census date for the current analysis (31 March 2021). 
2.8.2. Secondary outcomes 
The following were secondary outcomes included the original statistical analysis plan (Metcalfe et 
al, 2016); these are the pre-specified outcome measures now being addressed after a median of 
15 years follow-up. 
1) All-cause mortality at 10 and 15 years after start of follow up 
2) Definite or probable prostate cancer mortality at 15 years  
3) Disease stage and grade at diagnosis  
The primary outcome for the 15-year analysis is definite or probable prostate cancer mortality at 
median 15 years follow-up. We will add the diagnosis of prostate cancer metastasis as a secondary 
outcome, although this and proceeding with (3) Disease stage and grade at diagnosis, are 
dependent on being able to secure good quality data from routine sources on these outcomes. If 
some centres are only able to provide partial data (i.e. substantially less complete than other 
centres) on an outcome, we will present the findings both with and without such centres included. 
The definition of ‘partial data’ will be agreed and published online in advance of outcome analyses 
being conducted. 
CAP study estimates will be used in separate work (not covered by this plan) aimed at estimating 
age-specific lead time and over-diagnosis rates, and the projected lifetime effectiveness and cost-
effectiveness and cost-effectiveness of alternative UK-focussed PCa screening options. 
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3. GENERAL ANALYSIS CONSIDERATIONS 
3.1. Analysis populations 
The primary analysis set is all men aged 50 to 69 years registered with a participating practice on 
the date when the patient list was retrieved (the “list date”). Men were excluded as described in 
Section 2.4.2. 
3.2. Census and notification dates 
The census date for the current analysis is 31 March 2021. All outcome events occurring up to and 
including the census date, and which we are notified of by the 30th September 2021, will be 
included in the dataset extracted and locked for the current analysis.  
3.3. Derived variables 
To allow derived variables to be validated, they will be generated as part of the analysis code, with 
explanatory comments. 
3.4. Procedures for missing data 
Dates missing the day will be imputed as the 15th of the month. There will be no further 
imputation of missing data in the primary analysis of clinical effectiveness.  
3.5. Clustering 
General practices were the unit of randomisation in this cluster randomised trial, with the 
randomisation stratified by clusters of neighbouring practices. Any variation between 
randomisation clusters and between practices in the men’s outcome rates will be accommodated 
using randomisation cluster and practice-level random effects (i.e. a three-level model). 
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4. ASSESSMENT OF STUDY QUALITY 
4.1. Eligibility checks 
Patients already diagnosed with prostate cancer on the list date were identified through cancer 
registry data. Details of men were removed from the study database as soon as we were aware of 
their active objection to being included in the study. Details of men excluded by our consent 
procedure (see protocol), were not transferred from the ProtecT to CAP databases.  
4.2. Data validation  
Death due to prostate cancer is validated by an independent cause of death committee.  
4.3. Study completion 
Follow up is passive from each participant’s point of view and consequently follow-up is 
completed for almost all men. One exception is men who emigrate: we censor follow-up for these 
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5. ANALYSIS OF EFFECTIVENESS 
5.1. Summary of primary and secondary outcomes 
All estimates and graphical presentations will use the full data available to the end of follow-up 
once a median 15 years follow-up has been achieved (census date: 31 March 2021); follow-up of 
individual men will not be truncated at 15 years. 
The cumulative incidence of prostate cancer will be presented for the two intervention groups 
(Appendix, Figure 1), for all diagnoses, for different Gleason scores / grade groups separately, and 
for different disease stages (Appendix, Supplementary Figures A and B). Stage and grade at 
diagnosis will be presented as frequency tables, comparing the two intervention groups 
(Appendix, Table 1).  
The combined endpoint “Definite, probable, and treatment-related prostate cancer mortality” will 
be summarised for each intervention group at 10 and 15-year survival (estimated using the 
Kaplan-Meier method) with 95% confidence intervals (Appendix, Table 2). Cumulative incidence 
curves will be presented for each intervention group (Appendix, Figure 2). Similar statistics will be 
presented for all-cause mortality. 
Note that we have previously presented prostate cancer diagnosis and prostate cancer mortality 
up until 15 years. There are additional follow-up data available to this analysis for all time-points 
beyond seven years post-randomisation. In addition, the data previously presented are subject to 
small changes due to continued updates from NHS digital, the Office for National Statistics (ONS), 
and Public Health England (PHE). This explanation will be included in the report of the current 
analysis.  
5.2. Primary analysis 
The following Poisson regression model (1) incorporates the duration of follow-up for each man i 


















   (1) 
 
Variation in outcome between randomisation strata r=1,…,R (neighbouring groups of GP practices) 
will be accommodated by standard deviation σr of a level 3, zero mean, normally distributed 
random effect y0r, and variation in outcome between GP practices p=1,…P will be accommodated 
as standard deviation σp  of a level 2 zero mean normally distributed random effect. 
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As the incidence of prostate cancer diagnosis varies greatly by age, each man’s follow-up will be 
divided into the following current age-groups according to a lexis-diagram approach: 59 years or 
younger, 60-64 years, 65-69 years, 70-74 years, 75-79 years and 80 years or older. With a separate 
average baseline rate λ0j for each age group j, the assumption of a constant baseline rate will be 
reasonable for each separate age group separately. 
The intervention effect will be estimated as a rate ratio exp(β1), the coefficient for random 
allocation xi1 with value 0 for allocation to the comparison group and value 1 for allocation to the 
intervention group. These estimates will be presented with the prostate cancer mortality rate for 
each allocated group, after median study follow up of 10 years (corresponding to the primary 
analysis presented in Martin et al, 2018) and 15-years (Appendix, Table 3). 
5.3. Secondary analyses 
The analysis in section 5.2 will be adapted to the analysis of other mortality measures. 
The intervention effect on the rate of prostate cancer mortality will be estimated separately for 
the first ten years following the randomisation date, and for the subsequent years of follow-up. 
These estimates will be presented with their 95% confidence intervals, and a test of the null 
hypothesis that the intervention effect remains constant over the median 15 years follow-up. This 
is a similar approach to that taken by Schröder et al (2014) in analysing the ERSPC 13 years follow-
up data, with an increase in the size of the screening effect observed from a risk ratio of 0.88 over 
the first 0-4 years to 0.72 during years 8-12. 
Statistical methods will be employed that use random allocation as an instrumental variable, to 
estimate the effect of the invitation to the prostate check clinic in those who accept the invitation 
and attend the prostate check clinic. We will employ a generalized method of moments estimator, 
which takes advantage of the random allocation as a strong instrumental variable, to compare 
those men in the intervention group who attended the prostate check clinic, to the comparable 
men in the control group who would have attended the clinic if invited (Baum, 2013). Robust 
standard errors will be employed to accommodate any clustering of outcomes by GP practice. This 
analysis will employ Stata’s ivpoisson command, with the generalized method of moments 
estimator, multiplicative errors, and robust standard errors to allow for clustering: 
 
ivpoisson gmm pcadth (test = rand) [pw=w], 
 exp(exposure) mult vce(cluster practice_id) irr 
 
Where test indicates those men in the intervention group who attend the clinic, and rand 
indicates the randomly allocated group. A key assumption underpinning this approach is that the 
subsequent rate of prostate cancer mortality is the same in the men who do not attend the clinic 
in the intervention group and in those men in the comparison group who would not have 
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attended the clinic if invited (Metcalfe, 2013). This instrumental variable analysis will be applied to 
all outcome measures in Table 3 (see Appendix). 
To assist with the interpretation of the study results, Table 4 (see Appendix) will present prostate 
cancer diagnoses and prostate cancer deaths for men in the intervention group, against their 
findings in screening and the subsequent diagnostic pathway.  
5.4. Pre-specified sub-group analyses 
Sub-group analyses will examine whether the effect of intervention on the primary outcome varies 
by age group at baseline (50-54, 55-59, 60-64, 65-69+ years) and by index of multiple deprivation 
tertile. An interaction test p-value will be used to evaluate the evidence against the null hypothesis 
of equal intervention effect across sub-groups. If the association of outcome rate and age group / 
deprivation tertile is consistent with a linear trend, advantage will be taken of this to employ a 
single degree of freedom interaction test (Appendix, Table 5). 
5.5. Process analysis 
The analysis of age at diagnosis, stage and grade of prostate cancer will focus on men diagnosed 
with prostate cancer only. Mean age at diagnosis will be compared between intervention groups 
using ordinary linear regression. The proportions diagnosed over the 15-year average follow-up 
with Gleason scores of 6 or less, 7, and 8 or more (or Grade Groups 1, 2 and 3+ if the available 
data allow), or diagnosed with clinical stage T1/T2 disease, clinical T3, and T4/N1/M1 stage disease 
will each be compared between intervention groups using ordered logistic regression. Robust 
standard errors will be employed to allow for variation between GP practices. 
5.6. Sensitivity analysis 
Analysis of the primary outcome will be repeated in sensitivity analyses to include: (1) definite, 
probable, possible and treatment-related prostate cancer mortality; and (2) definite and 
treatment-related prostate cancer mortality (both estimates presented in text). 
It is not anticipated that deaths due to other causes (“competing risks”) will be associated with 
prostate cancer disease but, as deaths due to other causes will be substantial, we will present in 
the report text an estimate of the screening effect on the primary outcome with competing risks 
accommodated (Fine & Gray, 1999). We do not expect that the risk of deaths due to other causes 
will differ between allocated groups, but we will tabulate the data to allow this assumption to be 
tested (Appendix, Supplementary Table A).  
If it is not possible for the Cause of Death Committee to consider a number of deaths (i.e. due to 
COVID-19 measures), the impact of this on the estimated intervention effect on the primary 
outcome will be assessed using our estimates of death certificate accuracy (Turner et al 2016, 
Gilbert et al 2016). 
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As described in Section 2.8.2, if some centres are only able to provide partial data for the 
measures dependent on routine data (i.e. substantially less complete than other centres), we will 
consider presenting the findings both with and without such centres included. 
Should any of the management groups in the ProtecT trial be shown to be superior at 15-year 
median follow-up (i.e. reducing mortality), then any difference in prostate cancer or all-cause 
mortality between intervention and comparison groups will be less apparent than would be 
expected had a screening programme taken place when the optimal treatment(s) were the 
standard of care. In this case the beneficial effect on mortality of such an “optimal” screening 
programme, based on the (unbiased) treatment effect estimates from the ProtecT trial and the 
(unbiased) effect estimates from the CAP study will be the subject of a separate modelling study.   
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Figure 1. Incidence of prostate cancer Cumulative incidence of prostate cancer in the 
intervention (solid line) compared to control (long dash line) groups  over the 15 years median 
follow-up 
 
Figure 2a. Prostate cancer and treatment related mortality Cumulative incidence of definite and 
probable prostate cancer and intervention related mortality in the intervention (solid line) compared 
to control (long dash line) groups 
 
Figure 2b All-cause mortality Cumulative incidence of all deaths in the intervention (solid line) 




Supplementary Figure A. Cumulative incidence of prostate cancer in the intervention (solid line) 
compared to control (long dash line) groups: (i) Gleason score 6 or less, (ii) Gleason score 7, (iii) 
Gleason score 8+ 
 
Supplementary Figure B. Cumulative incidence of prostate cancer in the intervention (solid line) 
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Table 1. Characteristics of prostate cancer cases at the time of diagnosis 
 












Did not attend 
prostate check clinic 
n = 
Clinical features at diagnosis of prostate 
cancer: after the initial 18 months of 
follow-up 
   
Mean age (standard deviation)     
Gleason Score  , n (%)*     
≤6     
7     
≥8     
Missing     
Stage, n (%)*     
T1/T2      
T3      
T4/ M1/N1     
Missing     
Clinical features at diagnosis of prostate 
cancer: initial 18 months of follow-up 
   
Mean age (standard deviation)    
Gleason Score, n (%)*    
≤6    
7    
≥8    
Missing    
Stage, n (%)*    
T1/T2     
T3    
T4/ M1/N1    
Missing     
 
*Column percentage of diagnosed men in the indicated group and who have data recorded for this variable. 
 
 
Table 2. Prostate cancer specific survival and overall survival (Kaplan-Meier estimates) at 10 years and 15 years post-randomisation by 
random allocation and intention-to-screen estimate of the difference between groups 
 Intervention group Control group    
 Deaths Probability of survival 
(95% CI) 
Deaths Probability of survival 
(95% CI) 
  Survival difference  
(95% CI) 
Definite or probable prostate 
cancer death or IRD 
       
15-year survival        
10-year survival        
All-cause mortality        
15-year survival        
10-year survival        
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Table 3. Prostate cancer specific mortality and all-cause mortality by random allocation: intention-to-screen estimate and instrumental variable 







  Effect of screening 
amongst those attending 
clinic (N=xxx,xxx) 
 Deaths Deaths per 1000 
person years (95% CI) 
Deaths Deaths per 1000   
person years (95% CI) 
Rate ratio  
(95% CI) 
p-value1 Rate ratio 
(95% CI) 
p-value 
Definite or probable prostate 
cancer death or IRD 
        
At 15 years median follow-up         
At 10 years median follow-up2         
First ten years of each man’s 
follow-up 
        
Subsequent follow-up         
All-cause mortality         
At 15 years median follow-up         
At 10 years median follow-up2         
CI denotes confidence interval; IRD = intervention related death 
1. Likelihood ratio test of the null hypothesis “no difference in prostate cancer mortality between the groups”, adjusted for current age 
2. Subject to small changes compared to previously published estimates due to corrections received from NHS digital, the Office for National Statistics, and 
Public Health England  
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Table 4. Clinical outcomes in the CAP intervention group over 15 years median follow-up by diagnostic pathway findings 




PSA test non-attenders    
PSA test attenders    
  No valid test    
  No result    
  PSA<3ng/ml (screen negative)    
  PSA 20ng/ml+    
  PSA 3+ but <20ng/ml 
  (eligible for a biopsy)  
   
    No biopsy    
    Biopsy    
      Negative biopsy result    
      Positive biopsy result    
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Table 5. Planned sub-group analyses of prostate cancer specific mortality1 over median 15 years follow-up 
 Intervention group Control group   
  
Deaths 
Deaths per 1000 person 
years (95% CI) 
 
Deaths  
Deaths per 1000 person 





Age at baseline       
50-54       
55-59       
60-64       
65-69+       
Index of multiple 
deprivation (England) 
      
Tertile 1       
Tertile 2       
Tertile 3       
Index of multiple 
deprivation (Wales) 
      
Tertile 1       
Tertile 2       
Tertile 3       
1.  Definitely or probably due to prostate cancer or intervention related death, as established by the Independent Cause of Death Evaluation Committee 
2. Likelihood ratio interaction test of the null hypothesis of no difference in the comparison across the different subgroups 
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Supplementary Table A. Underlying causes of death (as recorded on the death certificate) 
in intervention versus control groups at 15-year median follow-up (not including prostate 
cancer deaths). 
Cause of death Intervention n (%) Control n (%) 
Any (not including prostate 
cancer deaths) 
  
Other cancers   
Ischaemic heart disease   
Stroke   
Other circulatory disease   
Respiratory disease   
Digestive disease   
Infectious disease   
Blood, immune, endocrine   
Nervous system disease   
Accident   
Other   
 
 
